TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02017405

Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.

Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.

Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.

Intervention type: OTHER
Group type: OTHER
Intervention: Matching Placebo
Study: NCT03299166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule once daily (QD)
Study: NCT01811992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
Description: Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care.
Study: NCT00905164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Capsules, 25 mg
Description: Topiramate Capsules, 2 x 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Capsules, 25 mg
Description: Topamax® Capsules, 2 x 25 mg
Study: NCT03422900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific enteral formula
Description: Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: Complete enteral formula normocaloric hormoproteic without fiber
Study: NCT03059134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 25mg
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 25mg
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 25mg
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg
Description: We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
Study: NCT03908801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized water dance intervention
Description: Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
Study: NCT00726063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanotite dental implant
Description: Nanotite root form titanium dental implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite dental implant
Description: Osseotite Root form titanium dental implant
Study: NCT00436696

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03111823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo aerobic exercise sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03414502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarilumab
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Starting dose which may be adjusted as needed at the discretion of the investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study: NCT03763084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
Study: NCT02705742

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal Stem Cells
Description: 1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
Study: NCT02928887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
Study: NCT00303069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose of saline placebo intramuscularly
Study: NCT01816217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with The McGrath Mac videolaryngoscope
Study: NCT04073173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INSURE
Description: Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INSURE
Description: Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA
Description: Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA
Description: Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic, Opioid
Description: Remifentanil (0.5-2 micrograms/kg/dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic, Opioid
Description: Remifentanil (0.5-2 micrograms/kg/dose)
Study: NCT00795613

Intervention type: DRUG
Group type: OTHER
Intervention: CONVENTIONAL ABVD
Description: ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
Study: NCT05994404

Intervention type: PROCEDURE
Intervention: ACDF

Intervention type: PROCEDURE
Intervention: Posterior Cervical Fusion
Study: NCT01959503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progel Vascular Sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam Plus
Study: NCT03010449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-bronchial valve and blood
Description: Intra-bronchial valve implantation in combination with autologous blood instillation
Study: NCT03554525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat-binder damm
Description: 3 sticks every day during 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 sticks every day during 12 months
Study: NCT03484754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: injection of botulinum toxina in two different facial sites

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin
Description: injection of botulinum toxina in two different facial sites
Study: NCT03544684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of the type of exercise on blood glucose concentrations
Description: glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
Study: NCT05994404

Intervention type: PROCEDURE
Intervention: Cervical Laminoplasty
Study: NCT01094379

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy using four entry sites to the abdominal cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy using one entry site to the abdominal cavity
Study: NCT02695303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT01398995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of basal insulin infusion to 50% of normal
Description: Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of basal insulin infusion to 50% of normal
Description: Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of basal insulin infusion to 50% of normal
Description: Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of basal insulin infusion to 50% of normal
Description: Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
Study: NCT04310033

Intervention type: OTHER
Intervention: Questionnaires
Description: Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone

Intervention type: OTHER
Intervention: Questionnaires
Description: Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
Study: NCT03598010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actitan-F (7dd)
Description: 1 sack every 4 hours, maximum 4 sacks/day for 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actitan-F (28dd)
Description: 1 sack every 4 hours, maximum 4 sacks/day for 28 days.
Study: NCT03102645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine Hydrochloride 25 MG
Description: Two Imipramin DAK film coated tablets 25 mg each, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine Hydrochloride 25 MG
Description: Two Imipramin DAK film coated tablets 25 mg each, single dose
Study: NCT01045408

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Berry extract
Description: Berry extract for weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Berry extract
Description: Berry extract for weeks
Study: NCT03069001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir-Simeprevir
Description: -Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir-Ribavirin
Description: -Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
Study: NCT01498029

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
Study: NCT03544684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of the type of exercise on blood glucose concentrations
Description: glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of the type of exercise on blood glucose concentrations
Description: glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
Study: NCT01806441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-days high fat diet
Description: During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-days low fat diet
Description: During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
Study: NCT01498029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System (CAIS)
Description: The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
Study: NCT01414504

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar + PPV
Description: 0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant PCV (Prevenar) + PPV at 9 months
Description: 0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: No Prevenar + PPV at 9 months
Description: no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control, 0.1mL Pneumovax at 3-5yrs
Study: NCT02575859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant HIPEC
Description: Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
Study: NCT03028038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Platelet Rich Plasma
Description: No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed.
Study: NCT03022279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Blocks
Description: ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local wound infiltration
Description: local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine